Letermovir

Letermovir
Clinical data

Routes of administration	Oral
ATC code	None
Legal status
Legal status	Investigational
Identifiers
IUPAC name {(4S)-8-Fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
Synonyms	AIC246
PubChem (CID)	45138674
ChemSpider	26352849
UNII	1H09Y5WO1F^Y
ChEMBL	CHEMBL1241951
Chemical and physical data
Formula	C₂₉H₂₈F₄N₄O₄
Molar mass	572.55 g/mol
3D model (Jmol)	Interactive image
SMILES COC1=C(C=C(C=C1)C(F)(F)F)N2[C@H](C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O
InChI InChI=1S/C29H28F4N4O4/c1-40-20-6-3-5-19(16-20)35-11-13-36(14-12-35)28-34-27-21(7-4-8-22(27)30)23(17-26(38)39)37(28)24-15-18(29(31,32)33)9-10-25(24)41-2/h3-10,15-16,23H,11-14,17H2,1-2H3,(H,38,39)/t23-/m0/s1 Key:FWYSMLBETOMXAG-QHCPKHFHSA-N

Letermovir (INN) is an antiviral drug that is being developed for the treatment of cytomegalovirus (CVM) infections. It has been tested in CMV infected patients with allogeneic stem cell transplants and may also be useful for other patients with a compromised immune system such as those with organ transplants or HIV infections.^[1]

The drug has been granted fast track status by the US Food and Drug Administration (FDA) and orphan drug status by the European Medicines Agency.^[1]

The drug candidate is under development by Merck & Co., Inc as investigative compound MK-8228.^[2]

References

1 2 "Neues Virostatikum Letermovir" (in German). Deutsche Apothekerzeitung. 2011-08-29.
↑ Masangkay, Estel Grace (July 29, 2014). "Merck Kicks Off Phase 3 Study Of CMV Drug Letermovir". Retrieved 8 Oct 2014.

This article is issued from Wikipedia - version of the 7/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.